Chronic Inflammation - T Regulatory Cells (Lecture 4)
An important lecture in the chronic inflammation series. T Regulatory cells (TRegs) and their function. Let's review this promising area of immunology.
Disclaimer:
This video is not intended to provide assessment, diagnosis, treatment, or medical advice; it also does not constitute provision of healthcare services. The content provided in this video is for informational and educational purposes only.
Please consult with a physician or healthcare professional regarding any medical or mental health related diagnosis or treatment. No information in this video should ever be considered as a substitute for advice from a healthcare professional.
A good reference diagram in the book:
FIGURE 15.6 Mechanism of action of CTLA-4. A, Cytotoxic T lymphocyte antigen 4 (CTLA-4) expressed on regulatory T cells (Tregs) or activated T cells can inhibit the activation of responding T cells on the same antigen-presenting cells (APCs) (in trans). B, CTLA-4 on regulatory or activated T cells binds to B7 molecules on APCs and removes these molecules from the surface of the APCs, making the B7 costimulators unavailable to CD28 and blocking T cell activation. This action of CTLA-4 is able to suppress immune responses best when B7 levels are low, enabling CTLA-4 to out-compete the lower-affinity receptor CD28.
References:
Textbook: Abbas, Abul K.; Lichtman, Andrew H.; Pillai, Shiv. Cellular and Molecular Immunology E-Book (p. 94). Elsevier Health Sciences. Kindle Edition.
URL list from Wednesday, May. 31 2022
Targeting IL-2: an unexpected effect in treating immunological diseases | Signal Transduction and Targeted Therapy
https://www.nature.com/articles/s41392-017-0002-5#:~:text=While%20IL%2D2%20is%20generally,unwanted%20immune%20responses%20and%20eventually
IL-2 administration increases CD4+ CD25(hi) Foxp3+ regulatory T cells in cancer patients - PubMed
https://pubmed.ncbi.nlm.nih.gov/16304057/
IL-2 administration increases CD4+CD25hi Foxp3+ regulatory T cells in cancer patients - PMC
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1473973/
IL-10-Dependent Amelioration of Chronic Inflammatory Disease by Microdose Subcutaneous Delivery of a Prototypic Immunoregulatory Small Molecule - PubMed
https://pubmed.ncbi.nlm.nih.gov/34305950/
Chronic Inflammation - StatPearls - NCBI Bookshelf
https://www.ncbi.nlm.nih.gov/books/NBK493173/
Inflammation - Wikipedia
https://en.wikipedia.org/wiki/Inflammation
Cytokines and Chemokines at the Crossroads of Neuroinflammation, Neurodegeneration, and Neuropathic Pain - PMC
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3753746/
Frontiers | Toll-Like Receptors, Associated Biological Roles, and Signaling Networks in Non-Mammals | Immunology
https://www.frontiersin.org/articles/10.3389/fimmu.2018.01523/full
Learning objectives of this video are the following :
1. Concept of self-tolerance and suppression.
2. Overview T-cell maturation in thymus.
3. Production of T regulatory cells.
4. Phenotypic markers & heterogeneity of T regulator cells.
5. Functions of T regulaory cells in immune system.
MD., MSc., MSc., BSc
Mobeen Syed is the CEO of DrBeen Corp, a modern online medical education marketplace. Mobeen is a medical doctor and a software engineer. He graduated from the prestigious King Edward Medical University Lahore. He has been teaching medicine since 1994. Mobeen is also a software engineer and engineering leader. In this role, Mobeen has run teams consisting of hundreds of engineers and millions of dollars of budgets. Mobeen loves music, teaching, and doing business. He lives in Cupertino CA.
Write A New Comment
1 Comments
kakavand@*.com
Aug 16 2024, 5:13 pm
This doesn’t refresh to test questions for cme. Please help